BioVie to Present Rationale for use of NE3107 for the Treatment of Alzheimer's Disease at 2021 Alzheimer's Association International Conference
July 22, 2021, 3:11 pm
BioVie Inc., a clinical-stage company developing innovative drug therapies for the treatment of liver disease, neurodegenerative disease and certain cancers, announced today that Poster 55458 entitled “ Rationale for an Anti-inflammatory Insulin Sensitizer in a Phase 3 Alzheimer’s Disease Trial” by Christopher L Reading,
